Gå offline med appen Player FM !
Episode: 46 - Leveraging Albumin and IgG FcRn-Mediated Regulation in Therapeutic Development
Manage episode 357947451 series 2967424
Jan Terje Andersen, professor of biomedical innovation in the Department of Pharmacology at the University of Oslo and research group leader in the Department of Immunology at the Oslo University Hospital, has spent nearly two decades studying neonatal Fc receptors (FcRns) and their interactions with prominent blood proteins albumin and IgG. He sits down with moderator Nimish Gera, vice president of biologics at Mythic Therapeutics, to discuss the unique properties of FcRn and how it can be leveraged for novel therapeutic development. Additionally, Andersen details the mechanics of FcRn binding, why it prolongs albumin and IgG half-lives, and notable FcRn technological advancements and research findings in animal and human models. He also talks about engineering blood proteins for optimal function and launching his new venture, Authera, the preclinical stage biotech company using an FcRn-centered platform to study the receptor’s versatility across multiple cell types.
Links from this episode:
University of Oslo
Mythic Therapeutics
Authera
66 episoder
Manage episode 357947451 series 2967424
Jan Terje Andersen, professor of biomedical innovation in the Department of Pharmacology at the University of Oslo and research group leader in the Department of Immunology at the Oslo University Hospital, has spent nearly two decades studying neonatal Fc receptors (FcRns) and their interactions with prominent blood proteins albumin and IgG. He sits down with moderator Nimish Gera, vice president of biologics at Mythic Therapeutics, to discuss the unique properties of FcRn and how it can be leveraged for novel therapeutic development. Additionally, Andersen details the mechanics of FcRn binding, why it prolongs albumin and IgG half-lives, and notable FcRn technological advancements and research findings in animal and human models. He also talks about engineering blood proteins for optimal function and launching his new venture, Authera, the preclinical stage biotech company using an FcRn-centered platform to study the receptor’s versatility across multiple cell types.
Links from this episode:
University of Oslo
Mythic Therapeutics
Authera
66 episoder
Alla avsnitt
×Välkommen till Player FM
Player FM scannar webben för högkvalitativa podcasts för dig att njuta av nu direkt. Den är den bästa podcast-appen och den fungerar med Android, Iphone och webben. Bli medlem för att synka prenumerationer mellan enheter.